Advancing Patient Care with Antibody-Drug Conjugate Therapies in HER2-Negative and HER2-Low Metastatic Breast Cancer

home / peer-exchange / advancing-patient-care-with-antibody-drug-conjugate-therapies-in-her2-negative-and-her2-low
Navigating HER2 Heterogeneity: Precision Pathways in Breast Cancer Treatment

EP. 1: Navigating HER2 Heterogeneity: Precision Pathways in Breast Cancer Treatment

December 23rd 2024

A panelist discusses how differences in HER2-positive, HER2-low, and HER2-negative status impact clinical decision-making.

Watch